Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,628 GBX | +0.55% | +1.80% | +1.28% |
Apr. 02 | RBC Lifts Diploma PT, Maintains Sector Perform Rating | MT |
Apr. 02 | Bernstein starts AstraZeneca at 'outperform' | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 32.82 and 28.97 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.78 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.28% | 6.07B | C | ||
+5.09% | 39.21B | B | ||
+5.67% | 7.13B | C+ | ||
-9.54% | 5.24B | B | ||
+25.27% | 1.61B | C+ | ||
+4.97% | 1.55B | D+ | ||
-12.37% | 1.16B | C | ||
+6.79% | 1.07B | - | ||
-4.41% | 1B | - | - | |
+2.45% | 988M | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DPLM Stock
- Ratings Diploma PLC